PTCT Earnings Date: Feb 18, 2027 (Estimated) — PTC Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PTCT's next earnings date?
PTC Therapeutics, Inc. (PTCT) is expected to report Q4 2026 earnings on Thursday, February 18, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.24 on revenue of $322.9M.
How did PTCT do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), PTC Therapeutics, Inc. posted EPS of -$0.62 versus the $0.14 estimate, a miss of 533.3%. Revenue was $357.8M against a $306.4M estimate.
How much does PTCT stock move after earnings?
PTCT beat EPS estimates in 4 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 6.7% (up or down) in the day after earnings.
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
🤖 AI Earnings Analysis
PTC Therapeutics delivered a strong commercial catalyst, beating revenue estimates by $52M and raising 2026 revenue guidance to $1.29–$1.32B, but the $0.62-per-share loss sharply missed expectations.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 0.14 | -0.62 | -533.26% | $357.8M | ❌ Miss | — | — | — |
| 2026-07-30 | Q2 2026 | 0.31 | 0.92 | +196.77% | $360.5M | ✅ Beat | -9.94% | -6.18% | -7.19% |
| 2026-05-07 | Q1 2026 | -0.41 | -0.03 | +92.68% | $272.6M | ✅ Beat | +14.27% | +12.76% | +9.89% |
| 2026-02-19 | Q4 2025 | -0.33 | -1.67 | -406.06% | $164.7M | ❌ Miss | +1.09% | -2.58% | -6.58% |
| 2025-11-04 | Q3 2025 | -1.14 | 0.20 | +117.54% | $211.0M | ✅ Beat | +5.98% | +9.01% | +14.96% |
| 2025-02-27 | Q4 2024 | -0.65 | -0.85 | -30.77% | $213.2M | ❌ Miss | +9.27% | +4.41% | +7.26% |
| 2024-11-07 | Q3 2024 | -1.44 | -1.39 | +3.47% | $196.8M | ✅ Beat | +3.07% | -1.35% | +11.87% |
| 2024-08-08 | Q2 2024 | -1.05 | -1.29 | -22.86% | $186.7M | ❌ Miss | -3.57% | +1.82% | -3.17% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $357.8M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 77.1% | $275.9M | +110.7% | $153.4M | $118.3M | $131.0M | $184.0M |
| Royalty | 22.8% | $81.7M | +15.4% | $36.4M | $57.6M | $70.8M | $79.4M |
| Collaboration and License Revenue | 0.1% | $229K | -97.5% | $986.2M | $2.9M | $9.3M | — |
By region
Q3 FY26 · $275.9M total
| Segment | Share | Revenue | YoY | Q4 FY23 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 63.0% | $173.8M | +208.1% | — | — | $56.4M | $159.4M |
| Non-US | 37.0% | $102.0M | +36.9% | $118.0M | $82.0M | $74.5M | $178.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.